Elekta, IMPAC integrate technologies

TriMed Staff | | Health Imaging | Screening
Elekta Inc. this week inked a collaborative agreement with IMPAC Medical Systems Inc. to connect its digital linear accelerators (Elekta Synergy and Precise Treatment system) with IMPAC's oncology information management products. The announcement was made at the 46th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Oct. 3 - 7, in Atlanta.

IMPAC expects to ship later this year an enhanced interface which will add a high-speed capability to Elekta's PreciseBEAM IMRT (intensity modulated radiation therapy) system. The high-speed performance enhancement also will be included in the DICOM-RT compliant linear accelerator interface the companies are jointly developing, Elekta said.

"This agreement will further improve connectivity for customers by expanding the use of new technology systems - offering our customers true integration along with the freedom to choose the products which best fit their needs," stated Laurent Leksell, president and CEO of Elekta.

"This is a collaborative development effort aimed at enhancing the process of delivering increasingly complex cancer treatments," stated Joseph K. Jachinowski, president and CEO of IMPAC.

TriMed Staff

Related Content

FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise
Singing radiologist pens song to clear up confusion about breast cancer screening recs
AI loaded onto mammography systems can flag possible cancers in real time to speed workflows
Over half of eligible women skip their mammogram

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup